Trevena (TRVN) Prices $50M Public Offering of Common Stock at $2.30/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall St edges up on AI enthusiasm, Mideast negotiation hopes
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices drop about 3% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Trevena Announces Pricing of $50 Million Public Offering of Common Stock
August 12, 2020 9:27 AM EDTCHESTERBROOK, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (Trevena or the Company), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced today the pricing of its previously announced underwritten public offering of 21,739,131 shares of its common stock at a public offering price of $2.30 per share. Trevena has also granted the underwriters a 30-day option to purchase up to 3,260,869 additional shares of common stock, at the public offering price, less underwriting discounts and commissions. The gross proceeds of the... More
